340B Drug Pricing Program
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater oversight by the federal government, but they also significantly outperform drug companies in terms of program compliance.
AHA Post-Acute Care Advocacy Alliance News Update - June 13, 2025
Advocacy is such an important part of what we do as hospitals and health systems — and what the AHA does on behalf of our field — to help ensure that we get the resources we need to care for our communities.
Not only are 340B Drug Pricing Program hospitals subject to disproportionately greater oversight by the federal government, they outperform drug companies in terms of program compliance to a substantial degree. These discrepancies underscore the need for increased federal oversight of drug…
340B Advocacy Alliance Bulletin for June 13, 2025
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.
The AHA June 4 filed an amicus brief (https://www.aha.org/amicus-brief/2025-06-04-aha-files-brief-defending-tennessees-340b-contract-pharmacy-law) in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law prohibiting drug companies from…
AHA files brief defending Tennessee’s 340B contract pharmacy law.
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate models” before they can be implemented, which the department has not yet done for any of the models pursued by the plaintiff drug companies.
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-…